Literature DB >> 21516440

Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging.

Jeong Rang Park1, Jin-Oh Choi, Hye Jin Han, Sung-A Chang, Sung-Ji Park, Sang-Chol Lee, Yeon Hyeon Choe, Seung Woo Park, Jae K Oh.   

Abstract

Whether the left ventricular (LV) mass index (LVMI) and LV volumetric parameters are associated independently with natriuretic peptide levels is unclear in hypertrophic cardiomyopathy (HCM). Therefore, we investigated which parameters have an independent relationship with N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in HCM patients using echocardiography and cardiac magnetic resonance imaging (CMR). A total of 103 patients with HCM (82 men, age 53 ± 12 years) were evaluated. Echocardiographic evaluations included left atrial volume index (LAVI) and early diastolic mitral inflow E velocity to early annular Ea velocity ratio (E/Ea). LVMI, maximal wall thickness and LV volumetric parameters were measured using CMR. The median value of NT-proBNP level was 387.0 pg/ml. The mean NT-proBNP level in patients with non-apical HCM (n = 69; 36 patients with asymmetric septal hypertrophy, 11 with diffuse, and 22 with mixed type) was significantly higher than in those with apical HCM (n = 34, P < 0.001). NT-proBNP level was negatively correlated with LV end-diastolic volume (LVEDV) (r = -0.263, P = 0.007) and positively with LVMI (r = 0.225, P = 0.022) and maximal wall thickness (r = 0.495, P < 0.001). Among the echocardiographic variables, LAVI (r = 0.492, P < 0.001) and E/Ea (r = 0.432, P < 0.001) were correlated with NT-proBNP. On multivariable analysis, non-apical HCM, increased maximal wall thickness and LAVI were independently related with NT-proBNP. Severity of LV hypertrophy and diastolic parameters might be important in the elevation of NT-proBNP level in HCM. Therefore, further evaluation of these parameters in HCM might be warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21516440     DOI: 10.1007/s10554-011-9876-4

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  24 in total

1.  Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Authors:  Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

Review 2.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

3.  Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy.

Authors:  Fotis K Panou; Vasiliki K Kotseroglou; John A Lakoumentas; Stavroula A Chrysanthopoulou; John A Armeniakos; Theodora Stratigou; Helen Veve; Apostolos A Zacharoulis
Journal:  Hellenic J Cardiol       Date:  2006 Nov-Dec

4.  Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy.

Authors:  K Nishigaki; M Tomita; K Kagawa; T Noda; S Minatoguchi; H Oda; S Watanabe; N Morita; K Nakao; H Fujiwara
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

5.  Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy.

Authors:  Edmundo Arteaga; Aloir Queiroz Araujo; Paula Buck; Barbara Maria Ianni; Rogerio Rabello; Charles Mady
Journal:  Am Heart J       Date:  2005-12       Impact factor: 4.749

6.  Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.

Authors:  Dulce Brito; J Sampaio Matias; Luís Sargento; Maria João Cabral; Hugo C Madeira
Journal:  Rev Port Cardiol       Date:  2004-12       Impact factor: 1.374

7.  Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy.

Authors:  Bulent Mutlu; Fatih Bayrak; Gokhan Kahveci; Muzaffer Degertekin; Elif Eroglu; Yelda Basaran
Journal:  Am J Cardiol       Date:  2006-10-12       Impact factor: 2.778

8.  Plasma brain natriuretic peptide concentration: impact of age and gender.

Authors:  Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

9.  New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy.

Authors:  Yo Murakami; Toshio Shimada; Shin-Ichi Inoue; Hiromi Shimizu; Yoko Ohta; Harumi Katoh; Ko Nakamura; Yutaka Ishibashi
Journal:  Can J Cardiol       Date:  2002-12       Impact factor: 5.223

10.  Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography.

Authors:  Stefano Caselli; Antonio Pelliccia; Martin Maron; Daria Santini; Danilo Puccio; Andrea Marcantonio; Natesa G Pandian; Stefano De Castro
Journal:  Am J Cardiol       Date:  2008-06-12       Impact factor: 2.778

View more
  8 in total

Review 1.  Cardiovascular imaging 2012 in the International Journal of Cardiovascular Imaging.

Authors:  Hiram G Bezerra; Ricardo A Costa; Johan H C Reiber; Frank J Rybicki; Paul Schoenhagen; Arthur A Stillman; Johan De Sutter; Nico R L Van de Veire; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2013-04       Impact factor: 2.357

2.  Comprehensive Proteomics Profiling Identifies Patients With Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in the Hypertrophic Cardiomyopathy Population.

Authors:  Bradley S Lander; Yanling Zhao; Kohei Hasegawa; Mathew S Maurer; Albree Tower-Rader; Michael A Fifer; Muredach P Reilly; Yuichi J Shimada
Journal:  Front Cardiovasc Med       Date:  2022-06-17

3.  Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques (Macaca mulatta).

Authors:  Yu Ueda; JoAnn L Yee; Amber Williams; Jeffrey A Roberts; Kari L Christe; Joshua A Stern
Journal:  Comp Med       Date:  2020-08-10       Impact factor: 0.982

4.  Association of NT-proBNP and hs-cTnT with Imaging Markers of Diastolic Dysfunction and Focal Myocardial Fibrosis in Hypertrophic Cardiomyopathy.

Authors:  Céleste Chevalier; Miriam Wendner; Anna Suling; Ersin Cavus; Kai Muellerleile; Gunnar Lund; Paulus Kirchhof; Monica Patten
Journal:  Life (Basel)       Date:  2022-08-16

Review 5.  Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies.

Authors:  Chirine Parsai; Rory O'Hanlon; Sanjay K Prasad; Raad H Mohiaddin
Journal:  J Cardiovasc Magn Reson       Date:  2012-08-02       Impact factor: 5.364

6.  Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Changlin Zhang; Rong Liu; Jiansong Yuan; Jingang Cui; Fenghuan Hu; Weixian Yang; Yan Zhang; Youzhou Chen; Shubin Qiao
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

7.  Effect of feline characteristics on plasma N-terminal-prohormone B-type natriuretic peptide concentration and comparison of a point-of-care test and an ELISA test.

Authors:  Sofia Hanås; Bodil S Holst; Katja Höglund; Jens Häggström; Anna Tidholm; Ingrid Ljungvall
Journal:  J Vet Intern Med       Date:  2020-03-22       Impact factor: 3.333

8.  Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy.

Authors:  Limin Liu; Shangyu Liu; Lishui Shen; Bin Tu; Zhicheng Hu; Feng Hu; Lihui Zheng; Ligang Ding; Xiaohan Fan; Yan Yao
Journal:  Clin Cardiol       Date:  2020-08-18       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.